| Literature DB >> 30132929 |
Sarah M Gunter1, Leroy Versteeg1, Kathryn M Jones1, Brian P Keegan1, Ulrich Strych1, Maria Elena Bottazzi1,2, Peter J Hotez1, Eric L Brown3.
Abstract
Trypanosoma cruzi 24 (Tc24) is a recently described B-cell superantigen (BC-SAg) expressed by all developmental stages of T. cruzi, the causative agent of Chagas disease. BC-SAgs are immunoevasins that interfere with the catalytic response available to a subset of natural antibodies comprising the preimmune (innate) repertoire. Electrophilic modifications of BC-SAgs facilitate the formation of highly energetic covalent reactions favouring B-cell differentiation instead of B-cell downregulation. Therefore, the aim of this study was to convert the inhibitory signals delivered to B-cells with specificity for Tc24 into activating signals after conjugating electrophilic phosphonate groups to recombinant Tc24 (eTc24). Covalent immunization with eTc24 increased the binding affinity between eTc24 and naturally nucleophilic immunoglobulins with specificity for this BC-SAg. Flow cytometric analyses demonstrated that eTc24 but not Tc24 or other electrophilically modified control proteins bound Tc24-specific IgM+ B-cells covalently. In addition, immunization of mice with eTc24 adjuvanted with ISA720 induced the production of catalytic responses specific for Tc24 compared to the abrogation of this response in mice immunized with Tc24/ISA720. eTc24-immunized mice also produced IgMs that bound recombinant Tc24 compared to the binding observed for IgMs purified from non eTc24-immunized controls. These data suggest that eTc24 immunization overrides the immunosuppressive properties of this BC-SAg.Entities:
Keywords: zzm321990Trypanosoma cruzizzm321990; B-cell superantigen; Tc24; catalytic antibodies; chagas disease; covalent vaccination; electrophilic vaccination
Mesh:
Substances:
Year: 2018 PMID: 30132929 DOI: 10.1111/pim.12585
Source DB: PubMed Journal: Parasite Immunol ISSN: 0141-9838 Impact factor: 2.280